Literature DB >> 27104777

MUSASHI-2 duels in myelodysplastic syndromes.

Tzu-Chieh Ho1, James Taggart1, Michael G Kharas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27104777      PMCID： PMC4968902          DOI： 10.1080/15384101.2016.1176401

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

Review 2.  Recent developments in myelodysplastic syndromes.

Authors:  Rafael Bejar; David P Steensma
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

3.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

Authors:  Nicolas Goardon; Emanuele Marchi; Ann Atzberger; Lynn Quek; Anna Schuh; Shamit Soneji; Petter Woll; Adam Mead; Kate A Alford; Raj Rout; Salma Chaudhury; Amanda Gilkes; Steve Knapper; Kheira Beldjord; Suriya Begum; Susan Rose; Nicola Geddes; Mike Griffiths; Graham Standen; Alexander Sternberg; Jamie Cavenagh; Hannah Hunter; David Bowen; Sally Killick; Lisa Robinson; Andrew Price; Elizabeth Macintyre; Paul Virgo; Alan Burnett; Charles Craddock; Tariq Enver; Sten Eirik W Jacobsen; Catherine Porcher; Paresh Vyas
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

4.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

5.  Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.

Authors:  Hyog Young Kwon; Jeevisha Bajaj; Takahiro Ito; Allen Blevins; Takaaki Konuma; Joi Weeks; Nikki K Lytle; Claire S Koechlein; David Rizzieri; Charles Chuah; Vivian G Oehler; Roman Sasik; Gary Hardiman; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2015-07-23       Impact factor: 24.633

6.  Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs.

Authors:  Sun-Mi Park; Raquel P Deering; Yuheng Lu; Patrick Tivnan; Steve Lianoglou; Fatima Al-Shahrour; Benjamin L Ebert; Nir Hacohen; Christina Leslie; George Q Daley; Christopher J Lengner; Michael G Kharas
Journal:  J Exp Med       Date:  2014-01-06       Impact factor: 14.307

7.  MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.

Authors:  James Taggart; Tzu-Chieh Ho; Elianna Amin; Haiming Xu; Trevor S Barlowe; Alexendar R Perez; Benjamin H Durham; Patrick Tivnan; Rachel Okabe; Arthur Chow; Ly Vu; Sun Mi Park; Camila Prieto; Christopher Famulare; Minal Patel; Christopher J Lengner; Amit Verma; Gail Roboz; Monica Guzman; Virginia M Klimek; Omar Abdel-Wahab; Christina Leslie; Stephen D Nimer; Michael G Kharas
Journal:  Nat Commun       Date:  2016-02-22       Impact factor: 14.919
  7 in total
  2 in total

Review 1.  Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Authors:  Michael G Kharas; Christopher J Lengner
Journal:  Trends Cancer       Date:  2017-04-08

Review 2.  RNA Regulators in Leukemia and Lymphoma.

Authors:  Camila Prieto; Michael G Kharas
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.